GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Beneish M-Score

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Beneish M-Score : -3.36 (As of May. 17, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.36 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Enanta Pharmaceuticals's Beneish M-Score or its related term are showing as below:

ENTA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.79   Med: -2.44   Max: 23.11
Current: -3.36

During the past 13 years, the highest Beneish M-Score of Enanta Pharmaceuticals was 23.11. The lowest was -3.79. And the median was -2.44.


Enanta Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Enanta Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Beneish M-Score Chart

Enanta Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.41 -3.47 -0.97 -3.50 -3.48

Enanta Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.27 -3.41 -3.48 -3.79 -3.36

Competitive Comparison of Enanta Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Enanta Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Beneish M-Score falls into.



Enanta Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Enanta Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9516+0.528 * 1+0.404 * 0.1665+0.892 * 0.8978+0.115 * 1.5031
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2251+4.679 * -0.063561-0.327 * 1.4007
=-3.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $39.79 Mil.
Revenue was 17.054 + 18.003 + 18.932 + 18.892 = $72.88 Mil.
Gross Profit was 17.054 + 18.003 + 18.932 + 18.892 = $72.88 Mil.
Total Current Assets was $351.03 Mil.
Total Assets was $413.56 Mil.
Property, Plant and Equipment(Net PPE) was $58.37 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.58 Mil.
Selling, General, & Admin. Expense(SGA) was $57.17 Mil.
Total Current Liabilities was $54.61 Mil.
Long-Term Debt & Capital Lease Obligation was $43.41 Mil.
Net Income was -31.157 + -33.407 + -28.107 + -39.065 = $-131.74 Mil.
Non Operating Income was 0 + 0 + 0 + 1.869 = $1.87 Mil.
Cash Flow from Operations was -28.601 + -24.988 + -21.602 + -32.128 = $-107.32 Mil.
Total Receivables was $46.57 Mil.
Revenue was 17.795 + 23.585 + 20.317 + 19.479 = $81.18 Mil.
Gross Profit was 17.795 + 23.585 + 20.317 + 19.479 = $81.18 Mil.
Total Current Assets was $271.14 Mil.
Total Assets was $326.45 Mil.
Property, Plant and Equipment(Net PPE) was $35.60 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.42 Mil.
Selling, General, & Admin. Expense(SGA) was $51.97 Mil.
Total Current Liabilities was $32.17 Mil.
Long-Term Debt & Capital Lease Obligation was $23.07 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(39.787 / 72.881) / (46.569 / 81.176)
=0.545917 / 0.573679
=0.9516

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(81.176 / 81.176) / (72.881 / 72.881)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (351.029 + 58.373) / 413.557) / (1 - (271.137 + 35.604) / 326.445)
=0.010047 / 0.060359
=0.1665

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=72.881 / 81.176
=0.8978

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.422 / (2.422 + 35.604)) / (2.583 / (2.583 + 58.373))
=0.063693 / 0.042375
=1.5031

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(57.166 / 72.881) / (51.972 / 81.176)
=0.784375 / 0.640238
=1.2251

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((43.412 + 54.608) / 413.557) / ((23.073 + 32.166) / 326.445)
=0.237017 / 0.169214
=1.4007

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-131.736 - 1.869 - -107.319) / 413.557
=-0.063561

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Enanta Pharmaceuticals has a M-score of -3.36 suggests that the company is unlikely to be a manipulator.


Enanta Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals (Enanta Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Terry Vance director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Scott T. Rottinghaus officer: Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or officer: Chief Scientific Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly director, officer: President and CEO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett officer: Treasurer and CFO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta director AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Headlines

From GuruFocus

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

By Business Wire Business Wire 05-09-2023